Riferimento farmaci
Sparsentan
Sparsentan is a medicine in the class genitourinary. It is used for nephropathy.
- Classe del farmaco: Genitourinary
- Indicato per: nephropathy
Ultimo aggiornamento Fonti: US FDA label
Per operatori sanitari — solo a scopo di riferimento. Questa pagina è una sintesi breve, non è un parere medico e non sostituisce il RCP ufficiale né il giudizio clinico. Verificare sempre prima di prescrivere o dispensare.
Il contenuto clinico di questa pagina è disponibile solo in inglese.
In breve
- Classe del farmaco
- Genitourinary
- Codice ATC
- C09XX01
- Forme farmaceutiche comuni
- compressa
- Interazioni note
- 139 (Controindicata: 24 · Maggiore: 30 · Moderata: 68 · Minore: 17)
- Nomi commerciali
- 2
- Paesi e mercati
- 2
Per cosa si usa
Come agisce
Single molecule that antagonizes the endothelin type A receptor (ETAR) and the angiotensin II type 1 receptor (AT1R), both thought to be involved in the pathogenesis of IgAN and FSGS.
Dose abituale nell'adulto (sintesi del foglio illustrativo)
IgAN (adults): start 200 mg orally once daily; after 14 days increase to 400 mg once daily, as tolerated
Gravidanza e allattamento
- Gravidanza
- Unsafe Contraindicated in pregnancy: in rats it caused craniofacial and skeletal malformations and fetal death at 10 times human exposure (endothelin and angiotensin blockade). Exclude pregnancy before and during treatment; use effective contraception until 1 month (EU) or 2 weeks (US) after stopping.
- Allattamento
- Unknown No human milk data. US label: do not breastfeed (possible infant low blood pressure); EU: should not be used while breastfeeding. LactMed has no data and repeats the maker's advice. Prefer not to breastfeed during treatment.
Effetti indesiderati segnalati
- Hyperkalemia
- Hypotension (including orthostatic hypotension)
- Peripheral edema
- Dizziness
- Anemia
- Acute kidney injury
Avvertenze in evidenza
- Hepatotoxicity: available only through the restricted FILSPARI REMS. Aminotransferase elevations of at least 3-times ULN occurred in up to 3.5% of patients. Measure transaminases and bilirubin before treatment and every 3 months; interrupt and monitor if above 3-times ULN. Generally avoid in patients with baseline aminotransferases above 3-times ULN.
Controindicazioni
- Pregnancy
- Concomitant use with ARBs, ERAs, or aliskiren
Chi deve prestare attenzione
- Hepatotoxicity: monitor aminotransferases and bilirubin; stop and seek medical attention if symptoms of liver injury occur.
- Hypotension: consider adjusting other antihypertensives; consider dose reduction or interruption if it develops.
- Acute kidney injury: monitor kidney function periodically; patients with renal artery stenosis, CKD, severe heart failure or volume depletion are at particular risk.
Informare il farmacista o il medico di gravidanza o allattamento, malattie renali o epatiche, allergie e di ogni altro farmaco o integratore assunto.
Interazioni principali (139)
- Aliskiren + Sparsentan Contraindicated
- Amlodipine-hydrochlorothiazide-valsartan + Sparsentan Contraindicated
- Amlodipine-olmesartan + Sparsentan Contraindicated
- Amlodipine-olmesartan-hydrochlorothiazide + Sparsentan Contraindicated
- Amlodipine-valsartan + Sparsentan Contraindicated
- Azilsartan + Sparsentan Contraindicated
- Azilsartan-chlorthalidone + Sparsentan Contraindicated
- Bosentan + Sparsentan Contraindicated
- Candesartan + Sparsentan Contraindicated
- Candesartan-hydrochlorothiazide + Sparsentan Contraindicated
Per gli utenti Pro+
Sblocca la pagina completa
Crei un account e avvii una prova di Pro+ per aprire la monografia completa di Sparsentan: dosi, gravidanza e allattamento, effetti indesiderati, avvertenze e tutte le interazioni.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Paediatric dosing
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
- IV preparation and dilution
Provi Pro+ gratis per 14 giorni sul web. Nessuna carta.
Domande frequenti
What is Sparsentan used for?
Sparsentan is a medicine in the class genitourinary. It is used for Nephropathy.
What side effects have been reported with Sparsentan?
Hyperkalemia, Hypotension (including orthostatic hypotension), Peripheral edema, Dizziness, Anemia, Acute kidney injury. Serious warning: Hepatotoxicity: available only through the restricted FILSPARI REMS.
Can Sparsentan be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Contraindicated in pregnancy: in rats it caused craniofacial and skeletal malformations and fetal death at 10 times human exposure (endothelin and angiotensin blockade). Exclude pregnancy before and during treatment; use effective contraception until 1 month (EU) or 2 weeks (US) after stopping. Breastfeeding: Unknown. No human milk data. US label: do not breastfeed (possible infant low blood pressure); EU: should not be used while breastfeeding. LactMed has no data and repeats the maker's advice. Prefer not to breastfeed during treatment.
What does Sparsentan interact with?
MediHelp lists 139 known interactions for Sparsentan. Contraindicated: 24 · Major: 30 · Moderate: 68 · Minor: 17. The most serious include Aliskiren, Amlodipine-hydrochlorothiazide-valsartan, Amlodipine-olmesartan.
Monografie complete, posologie e verifica delle interazioni nell'app MediHelp
Apra il riferimento completo, verifichi le interazioni tra più farmaci e usi gli strumenti di posologia nell'app MediHelp.
